A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

被引:36
作者
Cortes, J [1 ]
Kantarjian, H [1 ]
Albitar, M [1 ]
Thomas, D [1 ]
Faderl, S [1 ]
Koller, C [1 ]
Garcia-Manero, G [1 ]
Giles, F [1 ]
Andreeff, M [1 ]
O'Brien, S [1 ]
Keating, M [1 ]
Estey, E [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
angiogenesis; vascular endothelial growth factor; thalidomide; acute myeloid leukemia; myelodysplastic syndrome;
D O I
10.1002/cncr.11180
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti-angiogenic activity, this study was designed to investigate the potential role of Th in the treatment of patients with AML and MDS and the possible role of a non-ara-C-containing regimen. METHODS. Adults with AML or high-risk MDS and cytogenetic abnormalities other than inv (16), t(8;21), -Y or -X were randomized to receive liposomal daunorubicin (DNX) and ara-C (DA) or DNX and topotecan (DT). Within each arm, patients were randomized to receive chemotherapy alone (DA or DT) or with thalidomide (DATh or DTTh). Vascular endothelial growth factor (VEGF) plasma levels and microvascular density was measured before and after therapy. Eighty-four patients (median age, 65 years; range, 27-84 years) were treated. RESULTS. None of 11 patients treated with DT or DTTh responded and these arms were closed. Seventeen of 37 patients treated with DA and 15 of 36 treated with DATh achieved an early complete remission. Median complete response duration was 38 and 34 weeks (P = 0.57) and median survival 35 and 28 weeks (P = 0.15), respectively. Patients with high pretreatment VEGF levels had an inferior survival. There was no significant difference in the changes in VEGF levels or microvascular density after treatment in patients who did versus those who did not receive thalidomide. CONCLUSIONS. The authors concluded that thalidomide in combination with chemotherapy does not result in clinical benefit in patients with AML or high-risk MDS. (C) 2003 American Cancer Society.
引用
收藏
页码:1234 / 1241
页数:8
相关论文
共 38 条
[1]   Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].
Aguayo, A ;
Kantarjian, H ;
Manshouri, T ;
Gidel, C ;
Estey, E ;
Thomas, D ;
Koller, C ;
Estrov, Z ;
O'Brien, S ;
Keating, M ;
Freireich, E ;
Albitar, M .
BLOOD, 2000, 96 (06) :2240-2245
[2]   Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].
Aguayo, A ;
Estey, E ;
Kantarjian, H ;
Mansouri, T ;
Gidel, C ;
Keating, M ;
Giles, F ;
Estrov, Z ;
Barlogie, B ;
Albitar, M .
BLOOD, 1999, 94 (11) :3717-3721
[3]  
Belotti D, 1996, CLIN CANCER RES, V2, P1843
[4]   Therapy of untreated acute myeloid leukemia in the elderly: Remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide [J].
Bow, EJ ;
Sutherland, JA ;
Kilpatrick, MG ;
Williams, GJ ;
Clinch, JJ ;
Shore, TB ;
Rubinger, M ;
Schacter, BA .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1345-1352
[5]   REPORT OF THE NATIONAL CANCER INSTITUTE-SPONSORED WORKSHOP ON DEFINITIONS OF DIAGNOSIS AND RESPONSE IN ACUTE MYELOID-LEUKEMIA [J].
CHESON, BD ;
CASSILETH, PA ;
HEAD, DR ;
SCHIFFER, CA ;
BENNETT, JM ;
BLOOMFIELD, CD ;
BRUNNING, R ;
GALE, RP ;
GREVER, MR ;
KEATING, MJ ;
SAWITSKY, A ;
STASS, S ;
WEINSTEIN, H ;
WOODS, WG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) :813-819
[6]   Phase I study of liposomal daunorubicin in patients with acute leukemia [J].
Cortes, J ;
O'Brien, S ;
Estey, E ;
Giles, F ;
Keating, M ;
Kantarjian, H .
INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) :81-87
[7]  
Cortes J, 2001, CANCER-AM CANCER SOC, V92, P7, DOI 10.1002/1097-0142(20010701)92:1<7::AID-CNCR1285>3.0.CO
[8]  
2-D
[9]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[10]   Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB [J].
Estey, EH ;
Shen, Y ;
Thall, PF .
BLOOD, 2000, 95 (01) :72-77